 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
|
|
|
Phase II, Phase I
|
|
|
|
CCC-PHII-75
7435, NCI-7435, NCT00365157
|
|
| |
Randomized Phase II Study for Patients With Previously Treated Advanced Urothelial Cancer
|
|
|
|
Phase II
|
|
|
|
FER-GU-004
NCT00350025
|
|
| |
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
|
|
|
|
Phase II
|
|
|
|
MSKCC-06081
NCT00397488
|
|
| |
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
|
|
|
|
Phase II
|
|
|
|
UMCC 2005.145
NCT00393796
|
|
| |
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
|
|
|
|
Phase II
|
|
|
|
MAYO-MC0553
7661, MC0553, NCT00471536
|
|
| |
Gemcitabine, Paclitaxel, Doxorubicin, and Pegfilgrastim in Treating Patients With Metastatic or Unresectable Bladder Cancer or Urinary Tract Cancer and Kidney Dysfunction
|
|
|
|
Phase II
|
|
|
|
MDA-2005-0839
MDA-2005-0939, 2005-0839, 7341, NCT00478361
|
|
| |
Docetaxel With or Without Vandetanib in Treating Patients With Previously Treated Stage IV Transitional Cell Cancer
|
|
|
|
Phase II
|
|
|
|
DFCI-06116
FHCRC-6451, UWCC-UW-6451, UWCC-07-5533-H/D, 06-116, NCT00378794
|
|
| |
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
|
|
|
|
Phase II
|
|
|
|
CA182-026
NCT00633789
|
|
| |
Randomized Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
|
|
|
|
Phase II
|
|
|
|
UMCC 2007.097
NCT00645593
|
|
| |
A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer
|
|
|
|
Phase II
|
|
|
|
D2782C00010
NCT00661609
|
|
